ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Recruiting
105 enrolled
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Recruiting
50 enrolled
SCOUT-1
Recruiting
750 enrolled
IREN
Recruiting
500 enrolled
DP-04
Recruiting
100 enrolled
DUOLife
Recruiting
150 enrolled
BASECAMP-1
Recruiting
200 enrolled
OLIVIA
Recruiting
250 enrolled
SMARAGD
Recruiting
1,975 enrolled
EXoPERT EMERALD Clinical Study
Recruiting
1,400 enrolled
CAMPERR
Recruiting
7,000 enrolled
ELEPHAS-05
Recruiting
2,000 enrolled
CCANED-CIPHER
Recruiting
6,000 enrolled
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
Active not recruiting
354 enrolled
ELEPHAS-02
Recruiting
416 enrolled
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
Active not recruiting
1,150 enrolled
HERGYN
Completed
509 enrolled
Clinical Pre-screening Protocol for Ovarian Cancer
Recruiting
60 enrolled
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
Completed
1,018 enrolled
OVAL-1
Completed
342 enrolled
TraveraRTGx
Recruiting
200 enrolled
PROACTION:
Recruiting
4,500 enrolled
Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations
Recruiting
3,000 enrolled
Development of a Molecular Diagnostic Tool for Endometrial Cancer.
Completed
1,950 enrolled
ORACLE
Recruiting
2,020 enrolled
OLAP
Completed
661 enrolled
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Terminated
19 enrolled
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Completed
7 enrolled
RETRACE
Recruiting
200 enrolled
DESCENT-1
Enrolling by invitation
400 enrolled
OVARD
Active not recruiting
400 enrolled
START
Terminated
10 enrolled
Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting
Completed
2,506 enrolled
CYCLE_ENDO
Not yet recruiting
200 enrolled
BARHYSTER
Recruiting
132 enrolled
Tempus Priority Study: A Pan-tumor Observational Study
Active not recruiting
1,000 enrolled
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Withdrawn
PREFER
Completed
1,429 enrolled
ChemoINtel
Recruiting
100 enrolled
INSPIRE
Recruiting
5,350 enrolled
A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass
Recruiting
1,000 enrolled
GynRNA
Recruiting
2,500 enrolled
A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea
Completed
662 enrolled
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Withdrawn
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Active not recruiting
4,453 enrolled
QUANTUM
Enrolling by invitation
3,000 enrolled
Safety of Effivia®, a Bevacizumab Biosimilar
Completed
83 enrolled
EXCYTE-1
Terminated
13 enrolled
FLAME
Completed
24 enrolled
RADIANT
Completed
16 enrolled